# Chewable Tablet: A Review

Mr. Rahul Y. Pagar[1],Ms.Kajal Chaudhari[2*]Vaishnvi Katkar, Priyanka Pimpale, Namrata Amrute

[1,2]Department of Pharmaceutics,K.B.H.S.S. Trust's Institute of Pharmacy Malegaon(Nashik)

*Corresponding Author address:

**Ms. KajalChaudhari**

**Master of Pharmacy,**

Department of Pharmaceutics, K.B.H.S.S. Trust's Institute of Pharmacy Malegaon(Nashik)

**Email id**-kajalchaudhari700@gmail.com

**ABSTRACT**

Chewable dose forms, such as tablets, little pills, and gums, are a common tool in the drug specialist's toolbox. Before administration, they must be broken and chewed in the centre of the teeth.The advantages over solid dosage forms intended for swallowing include good bioavailability, improved patient consistency due to the removal of the need to swallow water, the potential use of solid dosage forms as a substitute where quick onset of action is required, and improved patient acceptance, such as when these tablets are given to children or patients who are unable to swallow. With or without chewing, these pills are made to dissolve swiftly and easily in the mouth. Chewable pills often dissolve smoothly, taste delicious, and don't leave behind any bitter or unpleasant aftertaste. Chewable tablet excipients' main ingredients are sweeteners and taste enhancers. The tablet is manufactured Using either wet granulation or direct pressure. The most crucial formulation parameters, which apply to both chewable and normal tablets, Flow, lubrication, disintegration, organoleptic properties, hardness, compatibility, and stability are some of the characteristics. This article discusses chewable pills, dysphasia, and their benefits and drawbacks.

**Keywords:** chewable tablets, children, dysphagia, flavouring agent, sweetener, compressibility.

## INTRODUCTION

The bulk of the tablets are made by pressing powder or granule mixes, with a small percentage made via moulding. The vast majority of pills are taken orally. Chewable, buccal, and sublingual tablets are examples of oral administration tablets. Before swallowing, tablets must be chewed and broken between teeth. Chewable pills should be broken down more slowly in the mouth, either with or without real biting. They crumble with a smooth surface, taste excellent, and leave no disagreeable aftertaste. Antacids, antidepressants, and antihelminthic medicines are all given as chewable pills. The key excipients in chewable tablets are taste and sweetness. The selection of appropriate excipients is critical to the development of a successful formulation. Sweeteners, both natural and man-made, are a typical excipient used in the manufacturing of chewable tablets to mask disagreeable flavours and boost child dose (by masking strong flavours). [1,2]Mannitol's non-hygroscopic properties make it a common excipient in chewable tablets for moisture-sensitive drugs. Dysphagia, as is widely known, affects individuals of all ages, although it is more prevalent in the elderly and while taking daily tablets and capsules. [3] In terms of manufacturing, precision dosing, mobility, and long-term durability, chewable tablets outperform regular tablets. Furthermore, because the chemical is first broken down into particles in the mouth when using a chewable tablet, swallowing is made easier. [4]

**.ADVANTAGES OF CHEWABLE TABLET[5-6]**

1. It is convenient to take once a day, especially for those who have trouble taking normal pills and capsules.
2. Lower the possibility of drug-induced esophagitis. This happens when the pill becomes stuck in the oesophagus and dissolves when in contact with the thin lining.
3. Delicious and available in a range of flavours
4. Convenient and simple to use.
5. Available in a single dosage; no quotation is necessary.
6. Increase reliability
7. Water-free dosage formats include: convenience to take everywhere, at any time; easy transport.

**DISADVANTAGE OF CHEWABLE TABLET[7]**

1) No bitter substances are used in the production of chewable tablets. No bitter substances are used in the production of chewable tablets.

2) Excessively fragrant chewable tablets might cause ulcerations.

3) Several excipients, some of which are hazardous to the body, are employed to give chewable tablets additional weight and enhanced features. For instance, sorbitol induces indigestion and diarrhoea.

4) Pain in the facial muscles with prolonged chewing of chewable pills

5) Due to their hygroscopic nature, chewable tablets should be properly packaged and stored in a dry environment.

6) Because chewable tablets have a low mechanical quality, they should be properly packaged and transported.

7) Shows bubbling, brittle granules..

**MATERIALS OR EXCIPIENTS USED IN THE PROMOTION OF CHEWABLE TABLETS[8-12]:**

Other than active pharmacological components or prodrugs, inactive pharmaceutical ingredients are those that are kept during the manufacturing process or are present in the finished pharmaceutical product. Excipients are crucial in the manufacturing of pharmaceutical dosage forms like:

1) Increased solubility and bioavailability of medicinal ingredients and excipients

2) Increased dosage structure and medication stability

3) Permit dynamic attachment to preserve ideal coordination or polymorphic structure.

4) Maintain the liquid formulations' pH and osmotic pressure.

5) It functions as an antioxidant, an emulsifier, an aerosol propellant, a binding agent, and a disintegrant.

6) Avoiding aggregation and separation

7) induce an immune response to the medication

8) To ship bulk pharmaceuticals

1. **Bulking agent or diluent:** These ingredients are used to increase the volume of chewable tablet formulations. The finished product has enough weight and bulk when combined with the medicinal component to make handling and production easier.
2. **Mannitol**

The diluent mannitol was frequently used. It is a desirable tablet bulking agent. The moment at which the flavour of chewable pills starts to matter The materials are essentially granules that are free-flowing, pure, crystalline, non-hygroscopic, and dormant. Because of the negative heat, sweetness, and "mouthfeel" of the chemical, it is widely used as a diluent in the manufacturing of chewable tablet formulations.Mannitol is thought to be roughly 70% sweeter than sucrose and is also used as a flavour enhancer. Powdered mannitol is appropriate for wet granulation. combined with an additional binder. available for direct printing procedures with a granular structure. By nature, mannitol is hygroscopic. Low-water-content mannitol is frequently used in formulations for products that are sensitive to moisture. Mannitol provides a very favourable environment for the creation of chewable tablets because of its powdery sweetness, mouthfeel, and non-hygroscopicity.

**3.Sorbitol**

An odourless, white, or almost hazy, crystalline, hygroscopic powder known as sorbitol occurs as a polyol. Tablets made using wet granulation or direct compression employ sorbitol as a diluent. It is commercially accessible as Crystalline Tablet Type (Pfizer Chemical) and SorbTab (ICI Americas) for direct printing. In order to produce a seductive, sweet flavour and offer a cooling effect, sorbitol is frequently used in priceless chewable tablet compositions. An isomer is Sorbitol is becoming progressively hygroscopic in comparison to mannitol.

**4.Dextrose**

The diluent dextrose is used in tablet formulations. The material, glucose, is colourless. They taste pleasant and have no smell. Enzymatic or acid hydrolysis of starch yields dextrose. Starches, such as maize or maize starch, are hydrolyzed. Dextrose is used as a diluent and binder in the form of wet granules. For instance, chewable tablets are the main form of dextrose, which is used in direct printing diluents and binders. Compared to sucrose, glucose is around 70% sweeter. Both monohydrate and anhydrous forms are offered. It compares lactose to a pill diluent as well. Tablets used to manufacture glucose monohydrate need more lubrication and have a tendency to clump right after printing.

**5.Lactose**

Another name for lactose is milk sugar. A disaccharide found in milk is lactose. After creating cheese and casein, lactose is the liquid that is still present in milk. In tableting, lactose is frequently employed as a diluent. It is a typical excipient for making tablets. Lactose plays a little part in chewable pills since it is less sweet. Compared to sugar, lactose is around 20% sweeter. Due to this insufficiency, a pseudo-sweetener must be added that has the power to combat lactose's blandness. For people who are lactose intolerant, chewable pills are inappropriate.

**6.Sucrose**

Sucrose is frequently used as a sweetener, diluent, and foil in wet granulation technology in tablet form. Simple sucrose crystals that have been compressed However, numerous modified sucroses have been employed in direct pressure regimens, which have never proven effective. (90–93% sucrose + 7–10% modified sugars), NuTab (2% each of 95% sucrose, 4% converted sugars, and 0.1–0.0 from cornflour and magnesium stearate), and other brands. For chewable tablets, the direct compression tableting procedure involves the addition of all sucrose-based diluents and binders. Avoiding fake sweeteners, in particular, is advised. There are more issues with using sucrose as a

bulking agent. Not decreased sugar, but sucrose is soluble. With time, it becomes darker. It is also hygroscopic and, when left to stand, takes on a cake-like texture.

**7.Flavouring agent**

Tablet excipients such as flavours are crucial. Chewable pills frequently have wonderful flavours, enhancements, and scents added with the help of spices. Oils are provided as solids, and spray-dried beads are included. Since these components are moisture-sensitive and have a tendency to evaporate quickly when heated, such as during the drying of wet granules, flavours are typically incorporated in the oil stage. Aqueous (water-soluble) flavours have not received much study because of their poor post-ageing stability. Oxidative processes weaken flavour consistency. Usually, dried acacia is used to emulsify oils in a spray. Compared to oils, dried flavours are simpler to manage and last longer. As the oil falls into the lubrication pan, it is often diluted with alcohol and sprayed into granules. Different varieties and tastes are

listed below the table of common benchmark flavour types.

| **Flavours** | **Group for Tasting Type** |
|---|---|
| **Sweet** | Vanilla,Fruits,Maple,Grape |
| **Sour(acidic)** | Raspberry,Anise,Cherry,Strawberry |
| **Salty** | Butterscotch, Buttery |
| **Bitter** | Coffee,Cherry,mint |
| **Metallic** | Burgundy,Lemom-Lime |

**Table 1. Flavour Types.**

**8. Sweeteners or taste enhancing agents[13]:**

In chewable tablets, sweeteners have an essential excipient role. When the taste of the active component or the active ingredient constituents cannot be entirely covered up by the regularly Sweeteners are typically added to chewable tablets in addition to carriers such as lactose, sucrose, mannitol, and dextrose. Artificial sweeteners should be used in these situations by product formulators to increase the overall sweetness variety. because artificial sweeteners may unintentionally cause cancer. e.g. saccharin and cyclamate. The main goal of pharmaceutical formulators is to create tablet goods without such knowledge. By definition, chewable tablets, and liquid indications, the taste-masking technique is the earliest and most basic type of taste-masking. However, this approach is not very efficient, particularly when dealing with powerful and extremely water-soluble medicines. In order to increase the efficacy of these tactics, fake sugars and flavours are frequently combined with other flavor-masking techniques.

| **Materials** | **Relative Sweetner** |
|---|---|
| Aspartame | 200 |
| Glycyrrhiya | 50 |
| Saccharin | 500 |
| Fructose(laevulose) | 1.7 |
| Lactose | 0.2 |
| Manitol | 0.5-0.7 |
| Sorbitol | 0.5-0.6 |

| | |
|---|---|
| Sucrose | 1 |
| Cyclamates | 30-50 |
| Dextrose(glucose) | 0.7 |
| Maltose | 0.3 |

**Table 2.Sweeteners or taste enhancing agents**

**Aspartame**

Aspartame is also known as A non-medicament-favoring artificial sweetener is called NutraSweet. It has a sweeter flavour than sucrose by a factor of several.Aspartame is at least as remarkable as regular sugar. Additionally, the use of aspartame in beverages, sweets, and cups of tea and coffee is recommended. Citrus flavours are enhanced and expanded with time. At room temperature, it is very dry and 50% muggy, although the aspartame arrangement is often stable at pH 4. Aspartame caused discoloration when tartaric and ascorbic acids were present; therefore, formulators often use less of it. Chewable pills frequently include it. Chewable pills contain 3 to 8 milligrammes of aspartame per tablet.

**Glycyrrhizin**

Glycyrrhizin is a liquorice-related substance with an amazing, lingering sweetness. Glycyrrhizin is another name for mangnasweet. These functional characteristics show how it can be used as a helper sweetener to increase sweetness levels while reducing residual flavour. Glycyrrhizin is often used at concentrations between 0.005 and 0.1%, with increasing fixes sometimes lending a faint licorice flavour. Saccharin Usually, chewable tablet sweeteners like saccharin are used. Saccharin is five hundred times sweeter than sucrose, as confirmed by the Food and Drug Administration (FDA). Saccharin's main drawback is an unpleasant delayed flavour perception. The adverse circumstances are destroyed by presenting the tiniest amount (1%) of sodium chloride. The saccharin delayed season sensation is definitely seen by 20% of the population or so. sweetness in general

**Colourants**

Chewable tablet formulations often include colourants for the following reasons:

1) To enhance purchasers' perception of exquisite application

2) The easiest in item differentiating proof and separation Three classes of coal tar tints were created by the 1938 Food Drug and Cosmetic Act, although only the Chewable tablets are made with FD and C tones and D and C conceals. The third representation (External D and C) is considered safe for usage in items applied remotely but is ineligible for use in goods intended for ingesting due to its oral hazard.

**FORMULATION FACTORS**

The composition of chewable tablets consists of numerous factors. Organoleptics, flow, disintegration, and other concepts are all used to explain how something functions. qualifications, and Each of these elements affects the formulation in some way. elements. The average person values stability and compatibility. On the other hand, the features of the active medication components are of primary relevance when it comes to organoleptic (swallowed) and chewable tablets. [14] here To produce a formula, a formulator may employ one or more procedures. determining a formulation and manufacturing technique that results in a product with exceptional organoleptic qualities The flow, compressibility, and stability of this chemical should be suitable. [15]

**TASTE AND FLAVOUR**

When the taste receptors on the tongue are chemically triggered, a sensory reaction called taste takes place. The four fundamental tastes are salty, sour, sweet, and bitter. Chemicals that may ionise in a solution are what give foods their salty and sour tastes. Despite their inability to ionise in an aqueous solution, many organic medicinal compounds cause a bitter reaction. Most saccharides, disaccharides, aldehydes, and alcohols have a sweet taste. A chemical is said to be tasteless if it has no effect on the sensory receptors in the buds. The word "flavour" describes a specific concoction of tastes and smells. For instance, honey has both a sweet flavour and a distinct perfume, in contrast to sugar, which has a sweet flavour but no aroma. [16]

**AROMA**

The term "aromas" refers to all pleasant fragrances together. For instance, a properly made A chewable orange pill should have the sweet-tart flavour and aroma of a genuine orange.

**MOUTH FEEL**

This term describes the The sensation or touch produced in the mouth cavity by chewing a pill. As a result, it has nothing to do with activating the olfactory nerve or taste receptors. Nonetheless, a composition's success depends much on how the mouth functions as a whole. Gritty or sticky textures, like calcium carbonates, are frequently detested, whereas relaxing and cooling sensations, like mannitol, are preferred.

Methods concerned with the tablet formulation [17]

Direct Compression

Wet granulation

Dry granulation

**Direct Compression**

When components are combined and pills are formed using a pill press, direct compression is used without any ingredient alteration. This approach isn't frequently employed since numerous tablets include active medicinal ingredients that might not highlight the consistency of the material for direct compression.

**Direct Compression Benefits**

effective in terms of cost

lower stability issues

excellent dissolution profile

streamlined validation process

**Direct compression has certain restrictions.**

low potential for diluting

sensitivity to lubricants

Various levels of practicality

**Dry Granulation**

Granulation is a process that creates links between particles to propel them forward. The powder is compacted using the dry granulation method without the use of heat or any other solvents. The two fundamental techniques are to compress a material into a compact state and then mill it to produce granules. The two main methods for dry granulation are Slugging, in which powder is recompressed and finished pills are polished to obtain granules, is the most often used method. Pre-compressing the powder using pressure rollers and a machine like a chiller is the alternative method. It primarily entails a number of processing procedures, including screening, compounding, and compression into finished tablets.




**Figure 1.Dry granulation method**

**Dry ganulation's benefits include:**

Less area power; affordability.

useful for moist, delicate material and warmth

Negative aspects of dry granulation

needs a dedicated heavy-duty pill press.

Uneven colour cannot be achieved.

creates more dirt and increases the risk of contamination.

**wet granulation**

Most indiscriminately, it is processed for granulation in the pharmaceutical industry. The only steps in the wet granulation process are Wet massing of powder mix with granulating liquid, wet sizing, and wet drying are all steps in the process

**The The granulation method consists of the following steps:**

drugs and receivers being mixed

Making a binder response

creating a wet ass by combining powder and binder Wet granules are dried.

blending of substance, glidant, and disintegrant with screened grains.

**Wet Granulation Has the Following Advantages:**

simplicity in mechanical handling

improve the powder's flow characteristics.

increases powder homogeneity and decreases air demurrer

decreases the likelihood of dirt and other types of contamination.

permits mixing liquid phasr with powder

converts hydrophobic surfaces into hydrophilic ones

Limitations of Wet Granulation:

Costly approach since it demands a lot of time, effort, and resources.

loss of fabric issues with thermolabile medication's stability

involves a time-consuming sequence of procedures

Problems with compatibility are frequently made worse.

**Physiology of Taste [18, 19, 20]**

A person's experience of taste may be described as a feeling when they take anything in their mouth to determine the entire component.




**Figure 2.Taste buds**

There are four basic elements of taste:

Sweet and salty, mostly on the tongue's tip

Sour on the tongue's side

bitter, lingering on the tongue

The human tongue includes 50-100 onion-shaped structures known as taste buds.

Chemicals Saliva dissolves substances from meals or medications taken orally. They either interact with taste receptors or ion channels on the surface of the cell. These interactions produce electrical changes inside taste cells,

causing them to send chemical messages to the brain in the form of neurotransmitters. Sweet and bitter reactions are surface protein responses, whereas salt and sour responses are channel-type responses. Changing concentrations of altered atoms or ions within the taste cell cause electrical reactions that relay the signal to the brain. These cells are normally negatively charged. Tastants alter the flavour by using a number of strategies to increase the concentration of positive ions inside the taste cell. As a result, taste cells depolarize, releasing neurotransmitters that urge neighbouring taste-related neurons to interact electrically with the brain. The bitter taste treatment stimulates the protein subunits of alpha, beta, and gamma to split and activate the enzyme by binding to G-protein-coupled receptors on the surface of the taste cell. The internal precursor of the cell is then converted into a "second messenger" by this enzyme. As a result of the second messenger, the taste cell's endoplasmic reticulum releases calcium ions. The buildup of calcium ion cells that results induces depolarization and the release of neurotransmitters. The impulses cause a feeling that is experienced as bitter. Taste receptors can be efficiently blocked by blocking the surface pore or competing with the taste receptors themselves to diminish the influence of bitter stimuli firing.

**Taste Masking**

Flavour masking is the term used to describe the elimination of an unwanted flavour. Taste-masking chemicals, certain scents, and sweeteners can all be used to cover certain tastes. Sweeteners are necessary to finish the experience and give the product a pleasing flavour. One of the main impediments to creating oral dosage forms with disagreeable tastes is this. The two main solutions to this issue are flavour masking and processing techniques. Flavour, sweetener, fat, and acid additions are frequently used to disguise flavours.

**Techniques for Taste Masking**

Chewable Tablet Evaluation Parameters [21]

When creating chewable pills, a range of assessment criteria must be considered.

These are listed below:

In-process organoleptic assessment Before formulation, there were certain frequent issues that were experienced, which are as follows: unpleasant flavour and mouthfeel. The ideal product should have a flavour and sweetness that are appropriate, a decent mouthfeel, and good compressibility. It should also avoid or minimise stimulation of the taste buds. These issues are resolved using the below methods:

1. Wet granulation coating
2. Microencapsulation
3. Solid agglomerations
4. Techniques for Formulating Adsorbates (Solvent Method)
5. Exchange of Ions
6. Congealing and coating with a spray
7. synthesis of various salts or derivatives
8. Utilisation of protein hydrolysates and amino acids
9. Integrated complexes

Chewable tablet development using molecular complexes Here are several examples [22, 23]:

1. **Drug evaluation:** The substance is characterised and compared in absolute terms or with a specified reference standard.

2. **Drug coating evaluation:** This includes comparing coated drugs to pure drugs and considering various coating treatments.
3. **Evaluation of the unflavored base formulation:** This entails comparing various vehicles, the percentage of vehicles, or other formulation factors when the medication is coated.
4. **Evaluation of the baseline taste formulation:** This step entails contrasting several flavour formulations.
5. **Product acceptability test and evaluation of the final selection:** This step compares two formulations or competing products.

Chemical Analysis It involves the following: [24–31]

1. Drug content testing
2. Consistency of dosage
3. Evaluation in vivo and in vitro

Physical Evaluation involves the following:

1. Tablet physical appearance
2. Hardness
3. Friability
4. Disintegration
5. Dissolution

**General Appearance, Diameter, and Thickness:**

**Size and Shape :**

According to component

requirements, tablet size and form must be adjustable and accurate. Dimensionally, you can monitor and control the size and condition of your tablet. The tool is in charge of controlling the printing process.

**Colour and Odour:**

Many pharmaceutical tablets use shading to make evidence easier to see and to make them more useful for customer reference. However, it needs to remain constant throughout batches, between tablets, and inside a single tablet. Tablet clusters' smell serves as a sign of stability problems. B. The smell of nutrients is distinctive. The patient's acceptance of chewable pills is significantly influenced by flavour. The most crucial dimension characteristic identified by this approach is tablet thickness, which is calculated to the nearest micron. Five or ten tablets can be arranged in various ways on the retaining plate, and the total thickness of the tablets can be calculated using the calliper scale. Tablet thickness should have a typical deviation of no more than 5%. The packaging of tablets also has an impact on thickness.

**Hardness:**

Use this tablet hardness tester to determine the hardness of tablets. This is an illustration of a Schleuniger hardness tester from Pfizer. The Monsanto hardness tester consists of two deloggers and a cylinder with a compression spring. There is no need to read through because the lower button hits the tablet. If not predetermined in each instance, spin the cocked jerk until the tablet breaks (40–60 N), and then press the top declamper against the spring. Appendix I of this Chronicle contains the definitions and justification for this file (Indicators of Difficulty Chewing). the transmission of chewing difficulty index data and the possibility of padding and agglomeration The force needed to

split pills depends on their hardness. The term "hardness" describes the strength or quality of a tablet. A Monsanto hardness analyzer or tester was used to measure the degree of hardness. The units of measurement are kg/cm2.

**Weight Variation:**

The weight The load of 20 tablets is controlled by simply computing the standard load and comparing the load of each tablet to the typical load as indicated in the USP weight grade study. Estimated breed test weights are provided as percentages. A pill is deemed to have passed the test by the USP if only two of its individual masses depart from the standard mass by an amount greater than the average deviation and not by a factor of two. (Starting weight minus Average Weight)/Average Weight x 100 equals the weight difference. A tablet's weight shouldn't vary from the average weight by more than 5%.

the USP weight grade study. Estimated breed test weights are provided as percentages.

| Sr. no. | Average weight tablets (mg) | Maximum % difference limits |
|---|---|---|
| 1 | 130 or less | ± 10.0 |
| 2 | 130 to 324 | ± 7.50 |
| 3 | More than 324 | ± 5.0 |

**Table 3. Weight Variation Limits for Tablets**

**Friability:**

Testing for friability reveals if tablets are capable of becoming less costly and of preventing abrasion during handling during shipping and packing. during the use of the Roche Friabilator. Weigh 10 pills, put them in the flibrator, and spin them 4 minutes at 25 rpm. The tablets were then removed, dusted, and tested again. The formula % Brittleness = [(starting weight - final weight)/initial weight]] 100 determines the rate at which tablets break. Time to Disintegrate: Six glass tubes with open tops that are 3 inches long make up the mechanical component of the USP collapse. These tubes are restrained by a 10-mesh screen at the base of a container rack. To evaluate the rate of deterioration, Placing the basket rack in the appropriate medium at 37 °C after placing one tablet into each cylinder The bottom never touches the cup's bottom by more than 1 inch. The basket assembly housing A common motorised device is used to move the tablet up and down across a distance of 5-6 cm at a pace of 28-32 cycles per minute.

**Drug Content Determination:**

Six glass tubes with open tops that are 3 inches long make up the mechanical component of the USP collapse. These tubes are restrained by a 10-mesh screen at the base of a container rack. He pours one tablet into each cylinder, and the basket stands in the appropriate medium at 37 °C to measure the disintegration time. The bottom never touches the cup's bottom by more than 1 inch. The tablet-containing Using standard motorised equipment at a frequency of 28-32 cycles per minute, the basket assembly is moved up and down a distance of 5-6 cm.

**In Vitro Dissolution Studies:**

Dissolution studies calculate the amount of time needed under various pH, volume, agitation, and temperature conditions for a specified proportion of the medication in a tablet to be removed. The look of the prescribed medication affects how well a medicine is absorbed from chewable tablets, whether they are intact or chewable. Chewable tablet in vitro disintegration testing currently requires adherence to commercial IR tablet disintegration testing standards. In vitro disintegration testing of whole tablets for product presentations in development should be

coordinated across all four media. To deliver medications in vitro, use USP Device 1 (basket), USP Device 2 (paddle), or USP Device 3 (piston cylinder). 900 mL of 0.1N HCl should be used as the vehicle. The filament revolved at 50 rpm while the temperature of the dissolving liquid remained constant at 37 0.5 °C. Samples were taken at 10, 20, and 30 minute intervals and replaced with an equal amount of brand-new dissolving medium. UV-Vis spectroscopy was used to evaluate the solution's absorption at wavelengths with highest and lowest absorbances of roughly 308 nm and 350 nm, respectively.

**Stability Analysis:**

To document the temporally dependent changes that take place in partial dosage structures, investigations on dosing structure or dosing item stability are carried out. Use of authorised stability-indicating test techniques to ensure active drug contentChanges in the physical qualities of tablets: mottling Strength tests can be time-based, animated, or evolve in a variety of ways. A problem's prospective quality alterations are foreseen through accelerated reliability testing. Tests for potency, disintegration speed, and in vitro dissolution were examined towards the conclusion of the term. Our stability programme includes many checks, like:with shadows, coloration of tablet surface, crystallisation of active ingredient on tablet surface, improvement of odour, etc. Tablet hardness, friability, solubility, and, in some cases, changes in solubility, increased disintegration time

Hygroscopic substances in tablets - Absorption of moisture by tablets leads to delicate tablets that disintegrate and sticky after chewing. When tablets lose moisture, they become brittle, and this brittleness increases. In addition, tablet hardness may increase.

Stability involves a scaffold that the polymers used in the taste-masking process must not degrade, facilitating the presentation of dynamic drug particles. Casings and grids should also be stable and ensure taste safety.

Pigment Stability: Colour tablets shouldn't have bleed-through or migratory pigments. Testing for colour stability includes techniques including tristimulus alignment with standards and introductory quality.

**Use of Chewable Tablets [32]**

1. **Local therapy:** The controlled release of an active substance from a chewable tablet over an extended period of time.
2. **Pain:** Rapid absorption of therapeutic amounts of the active component is required for the effective treatment of minor pains, headaches, cold-related discomfort, muscular aches, and other symptoms. Chewable tablets may be useful for treating mild pain since buccal absorption produces a rapid beginning of action and lowers the possibility of gastrointestinal adverse effects.
3. **Systemic Therapy:** Chewable tablets can help in systemic drug distribution, especially if the active component is absorbed through the buccal mucosa.
4. Nicotine, lobeline, and silver acetate chewing gum formulations have been studied as smoking cessation aids in clinical trials.
5. **Obesity:** Caffeine, guarana, and chromium-containing chewing gum formulations are available. Caffeine and guarana are centrally stimulating anorectic drugs that have been demonstrated to speed up metabolism.

**MARKETED PREPARATION OF CHEWABLE TABLET[33 – 60]]:**

| **Brand Name** | **Active Constituent** | **Category** | **Indication** | **MFG. By** |
|---|---|---|---|---|
| Claritin[33] | Loratidin | Antihistamine | Running nose, sneezing, | Bayer |
| Montair[35] | Montelukast | Antiasthmatic | Sneezing, Asthama Attack | Cipla Ltd. |
| Lamictal[36] | Lamotrigine | Anticonvulsant | Seizure | Glaxosmithkline |
| Mylanta Gas Minis [37] | Simethicone | Gastrointestinal Agent | Relieve Flatulence | McNeil Consumer Pharmaceutical Company |
| Danacid | Magnesium Trisilicate | Antacid | Heart Burn, Acid Indigestion | Dana Pharmaceutical Ltd. |
| Lipitor[38] | Atorvastatin | Antihyperlipidemic Agent | Hypertension | Pfizer |
| Natecal D3 | Calcium, cholecalciferol | As a vitamin | Calcium Dificiency | Chiesi Ltd. |
| Imodium Advanced[39-40] | Loperamide Hydrochloride , Simethicone | Antidiarroaheal | Dirrohea, Irritable Bowel Syndrome[IBS] | McNeil Consumer Pharmaceutical Company |
| Tylenol[41] | Paracetamol | Analgesic , Antipyretic | Fever & Pain | McNeil Consumer Pharmaceutical Company |
| Epanutin[42] Infatabs | Phenytoin | Anti Convulsants | Seizure | Pfizer |
| Limcee[43] | Ascorbic acid | As a Vitamin | Immuno Stimulant | Abbott pharmaceutical Ltd. |
| Fosrenol [44] | Lanthanum | Phosphate Binder | Lower High Phosphate Level | Shire US Inc. |
| Equalactin[45] | Polycarbophil | Laxative | Constipation | Numark |

| | | | | |
|---|---|---|---|---|
| | | | | Laboratories |
| Draminate[46] | Dimenhydrinate | Anticholinergic Antiemetics | Motion Sickness | RPG Lifesciences Ltd |
| Travel-[47] Ease | Meclizine | Anticholinergic Antiemetics | Dizziness | Travel-Ease Ltd. |
| Tegretol[48] | Carbamazepine | Anticonvulsants | Seizure | Novartis India Ltd. |
| Motrin[49] | Ibuprofen | Non-Steriodal | Arthritis | Johnson & Johnson. |
| Methylin[50] | Methylphenidate | CNS Stimulant | Narcolepsy | SpecGx LLC Webster Groves |
| Vyvanse | Lisdexamfetamine | CNS Stimulant | Binge Eating Disorder | Shire LLC. |
| Zyrtec | Cetrizine | Antihistamines | Hives | Dr. Reddy's Laboratories |
| Lactaid[51] | Lactase | Digestive Enzyme | Break Down Dairy Product | McNeil Nutritionals |
| Amoxil | Amoxicillin | Aminopenicillins | Bacterial Infections | Zydus Healthcare Limited. |
| Augmentin[52] | Amoxicillin and Clavulanate | Beta-Lactamase Inhibitors | Bacterial Infections | Glaxo Smithkline Pharmaceutical Ltd. |
| Suprax[53] | Cefixime | 3rd Generation Cephalosporin | Bacterial Infections | Elder Pharmaceutical Ltd. |
| Availnex | Carbocysteine | Anti-Asthmatic | COPD | Hall Bioscience Corporation. |
| Pepcid[54] | Famotidine | H2 Antagonist | Gastroesophageal Reflux | Nicholas Piramal India Ltd. |
| Luride[55] | Sodium Fluoride | Minerals & Electrolyes | Cavities | Bios Lab Pvt. Ltd. |
| Milk of Magnesia[56] | Magnesium Hydroxide | Antacids & Laxative | Constipation & Heart Burn | Deys Medical Pvt. Ltd. |
| NataChew[57-59] | Prenatal Vitamin | Iron Products& Vitamin | Aid wiith Diet Of Pregnancy | Eckson Labs |
| Bismarex[60] | Bismuth Subsalicylate | Antidiarrheal | Diarrhea | Rexall Drug Comapany Ltd. |
| Prosteon | Mineral & Vitamin | Mineral & Vitamin | Growth | Albion Laboratories |

**CONCULSION:**

Chewable tablets are flexible dosage forms that combine the benefits of solid products' durability and manufacturability with positive organoleptic and administration effects. Non-specific populations like paediatrics and differentiated pharmaceuticals have been pushed by the growing emphasis on patient-centred formulation in medication delivery, as have other populations including nutritional goods, dietary supplements, and veterinary treatments. Additionally, there is additional potential to employ chewable tablets in the healthcare sector.

**REFERANCES**

1. Lachman L, Liberman HA and Joseph B. Sachwartz. Theory and Practice of Industrial Pharmacy, Vargese Publication House, 2ndEdition, 1989, 367-368.
2. Lachmann L, Liberman HA, Schwartz JB. Pharmaceutical Dosage Forms. New York: Marcel Dekker Inc, 1989, 2(1).
3. Patel Y, Shukla A, Saini V, Shrimal N, Sharma P. Chewing Gum as a drug delivery system. International Journal of Pharmaceutical Sciences and Research. 2011;2:748-57.
4. Nyamweya N. and kimani S. ,Chewable Tablet :A Review of Formulation Consideration Pharmaceutical Technology 2020,44(11),38-44
5. Lachman L, Liberman HA, Kanig LJ. Theory and Practice of Industrial Pharmacy, Vargese Publication House, 3rd Edition, 1990, 293-336.
6. Pagar V Vijay , Sonawane P. Mitesh, Kothawade D. Parag, A Review on Chewable Tablet and its Granulation Techniques International Journal of Creative Research Thoughts, Volume 11, Issue 4 April 2023,521-536.
7. www.solid dosage forms.com
8. Lachmann L, Liberman HA, Schwartz JB. Pharmaceutical Dosage Forms. New York: Marcel Dekker Inc, 1989, 2(1)
9. Lachmann L, Liberman HA, Schwartz JB. Pharmaceutical Dosage Forms. New York: Marcel Dekker Inc, 1989, 2(1)
10. Rowe, R., Sheskey, P. and Quinn, M. (2009). Handbook of Pharmaceutical Excipients. USA: Pharmaceutical Press and American Pharmacists Association.
11. Patel H, Shah V, Upadhyay U. New pharmaceutical excipients in solid dosage forms. International Journal of pharmacy and life sciences. 2011, 2(8).
12. Orally Disintegrating Tablet and film technologies. Second edition, 2004, 177.
13. Sohi H, Sultana Y, Khar RK. Taste Masking Technologies in Oral Pharmaceuticals : Recent Developments and Approaches. 2004;30(5):429–48.
14. Jasvinder S.,Kumar k. , Saini P. , Panchal M , Thakur G., Rana P. FORMULATION AND EVALUATION OF CHEWABLE TABLET: AREVIEW INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 2022, 09 (6), 249-253
15. Donald, I.W., Hand book of pharmaceuticals controlled release technology. 1st ed. 2005: Marcel Dekker.

16. Nageswarao M .Udaykumar Kumar ABN, VTVS, Giri VV. Fast Dissolving Tablets: New Fangled Drug Delivery System, A Comprehensive Review. International Journal of Research in Drug Delivery. 2012; 2(3):15- 18
17. Parik.M, Handbook of Pharmaceutical Granulation Technology (Drugs and the Pharmaceutical Sciences, ed. Dilip. Vol. 81. 2009.
18. Smith DV, Margolskee RF. Making sense of taste. Scientific America 2001; 284(3):36.
19. Nanda AR, Garg KS. An update on taste masking technologies for Oral pharmaceuticals. Indian journal Pharma. sci. 2002; 64(1).
20. Roche. Roto-granulations and taste masking coatings for preparation of chewable pharmaceutical tablets. US Patent 5 260 072 9 November, 1993.
21. Khar RK, Sohi H. Taste masking technologies in oral pharmaceuticals: Recent development and approaches. Drug. Dev. Ind. Pharma 2004: 30:429,448.
22. Kathiresan K, Vijin P, Moorthi C, Manavalan R. Formulation and Evaluation of loratadine chewable tablets. Research Journal of pharmaceutical, Biological and chemical sciences. 2010; 1(4):765.
23. Renu, Dahiya J.,P. Jalwal , singh B., Chewable Tablets:A Comprehensive Review the Pharma Innovation Journal 2015;4(5):100-105.
24. Penniston KL, Tanumihardjo SA: The acute and chronic toxic effects of vitamin International Journal of Pharmaceutical Research and Applications Volume 8, Issue 1 Jan-Feb 2023, pp: 599-613
25. Olson JM, Ameer MA, Goyal A: Vitamin A Toxicity . [Article]
26. Health Canada: Dietary Reference Intakes [Link].
27. Malode A.: Goldenberg MM, Honkomp LJ, Burrous SE, Castellion AW: Protective effect of Pepto-Bismol liquid on the gastric mucosa of rats. Gastroenterology. 1975 Sep;69(3):636-40. [Article]
28. Budisak P, Abbas M: Bismuth Subsalicylate . [Article]
29. Medically reviewed by Drugs.com. Last updated on Sep 13, 2022.
30. Chavan H., Chhabra G, Gujarathi N., Jadhav A. COMPARATIVE STUDY OF INPROCESS AND FINISHED PRODUCTS QUALITY CONTROL TEST FOR TABLET AND CAPSULES ACCORDING TO PHARMACOPOEIAS
31. Md. Uddin S , Abdullah In-process and finished products quality control tests for pharmaceutical tablets according to Pharmacopoeias Al Mamun, Tanjuma Tasnu and Md. Asaduzzaman Department of Pharmacy, Southeast University, Dhaka-1213,
32. Rajesh M, Varghese BS, PR SQ. Formulation and evaluation of sugar free sucralfate chewable tablets. World J Pharm Res. 2017 Sep 11;6(14):846-58.
33. Shanmugam S. Granulation techniquesand technologies : recent progresses. 2015;5(1):55–63.
34. Medically reviewed by Sophia Entringer, PharmD. Last updated on Oct 9, 2021.
35. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [Article]
36. Obradovic T, Dobson GG, Shingaki T, Kungu T, Hidalgo IJ: Assessment of the first and second generation Antihistaminesbrain penetration and role of P- glycoprotein. Pharm Res. 2007 Feb;24(2):318-27
37. Tripathi KD. Drugs for Cough and Bronchial Asthma. Respiratory Drugs. Essentials of Medical Pharmacology. 7th Edition. 2013. Page – 228.

38. . Barbara K., MD, Alan Hartford, PhD, Xiujiang (Susie) Li, PhD, Amy Yifan Yang, MS, Gertrude Noonan, BA and Elizabeth Migoya, PharmD. Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast. NIH. National Library of Medicine. National Center for Biotechnology Information. PMC. PubMed Central. June 2010. [Accessed on29th October 2022]
39. https://www.ncbi.nlm.nih.gov/pmc/articles
40. Glenmark Pharmaceuticals s.r.o. Electronic Medicines Compendium (EMC). [Revised in October 2020][Accessed on 29th October 2022] https://www.medicines.org.uk/emc/files/pil.9916.pdf
41. Cipla Ltd. MONTAIR Tablets / Chewable Tablets / Oral Granules (Montelukast sodium). Ciplamed.com. [Revised inNovember 2019]. [Accessed on 29th October 2022]
42. https://www.ciplamed.com/content/montair-tablets-chewable-tablets-oral-granules
43. Medically reviewed by Drugs.com. Lastupdated on Jul 18, 2022.
44. Medically reviewed by Drugs.com on Oct24, 2022. Written by Cerner Multum.
45. KD. Tripathi. Insulin, HypolipidemicDrugs and Plasma Expanders. Essentials of medical pharmacology. Seventh Seventh edition. 2013. Page – 637.
46. https://pubmed.ncbi.nlm.nih.gov/1819296
47. Sahi N, Nguyen R, Santos C. Loperamide. NIH National Library of Medicine; National centre for Biotechnology Information. [Revised in May 2022] [Accessed on 16th September 2022]
48. .https://www.ncbi.nlm.nih.gov/books/NBK 557885/
49. Tillomed Laboratories Ltd. Electronic Medicines Compendium (EMC). [Revised in January 2022] [Accessed on 16th September 2022] https://www.medicines.org.uk/emc/files/pi l.11853.pdf
50. Cipla (EU) Limited. Electronic Medicines Compendium (EMC). [Revised in August 2020] [Accessed 16th September 2022] https://www.medicines.org.uk/emc/produc t/10287/smpc#gref
51. Tripathi KD.. Anthelmintic Drugs. Essentials of medical pharmacology. Seventh Edition. 2013. Page – 850.
52. Kashif M., Anterpreet Dua. Albendazole. NIH. National Library of Medicine. National Center for Biotechnology Information. StatPearls [Internet]. [Revised in May 2022] [Accessed on 7th October 2022]

[https://www.ncbi.nlm.nih.gov/books/NBK 553082/

53. Mian Zi Tee, Soo Ching Lee, Yi Xian Er, Nan Jiun Yap, Romano Ngui, Alice V. Easton, Vinnie Wei Yin Siow, Kee Seong Ng, Christopher Chiong Meng Boey, Kek Heng Chua, Ken Cadwell, P'ng Loke, Yvonne Ai Lian Lim. Efficacy of triple dose albendazole treatment for soiltransmitted helminth infections. PLOS ONE. August 2022. [Accessed on 7th October 2022].
54. https://journals.plos.org/plosone/article?id =10.1371/journal.pone.0272821
55. GlaxoSmithKline South Africa (Pty) Ltd. ZENTEL Tablets 200 mg and Suspension 20 mg/ml. [Revised in October 2015]. [Accessed on 7th October 2022]. https://gskpro.com/content/dam/global/hc pportal/en_ZM/PI/Zentel-20-ml-sus-and200-mg-tablets-GDS23.pdf
56. Kis B, Snipes JA, Busija DW: Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther. 2005Oct;315(1):1-7. Epub 2005 May 6. [Article]
57. Aronoff DM, Oates JA, Boutaud O: New insights into the mechanism of action of Acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two Prostaglandin H2 synthases. Clin Pharmacol Ther. 2006 Jan;79(1):9-19. [Article]

58. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S: Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006 Fall-Winter;12(3-4):250-75. [Article]
59. Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet. 2007 Jul 14;370(9582):185-191. doi: 10.1016/S0140-6736(07)61092-7. [Article]
60. Fischer JH, Patel TV, Fischer PA: Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet. 2003;42(1):33-58